CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal ca...
Phase 3
Berlin, Germany and 42 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Berlin, Germany and 125 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Berlin, Germany and 213 other locations
to chemotherapy and in maintenance, in patients with low grade ovarian cancer (including patients with primary peritoneal and / or...
Phase 2
Berlin, Germany and 1 other location
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Berlin, Germany and 113 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Berlin, Germany and 63 other locations
chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and /...
Phase 3
Berlin, Germany and 74 other locations
This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo...
Phase 2
Berlin, Germany and 5 other locations
in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...
Phase 3
Berlin, Germany and 117 other locations
placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1s...
Phase 3
Berlin, Germany and 110 other locations
Clinical trials
Research sites
Resources
Legal